



1<sup>st</sup> December 2021

Deputy Cormac Devlin,  
Dáil Éireann,  
Leinster House,  
Kildare Street,  
Dublin 2.

PQ 55642/21 - To ask the Minister for Health the number of authorised continuous glucose monitors by a company (details supplied) by CHO and LHO to those patients aged under 21 and over 21, respectively in tabular form; and if he will make a statement on the matter.

- Cormac Devlin

Dear Deputy Devlin,

The Health Service Executive (HSE) has been requested to reply directly to you in the context of the above Parliamentary Question (PQ 55642/21) which you submitted to the Minister for Health for response.

In response to your query, please see the tables below which provide the relevant information on Continuous Glucose Monitoring. The information covers the period 1.10.20 - 31.09.21.

Table 1

Age Group	Dexcom	Medtronic	Total
21 and older	3,831	764	4,595
Younger than 21	1,327	220	1,547
<b>Total Patients</b>	<b>5,158</b>	<b>984</b>	<b>6,142</b>

Table 2

CHO	Sum of Dexcom Transmitters*	Sum of Medtronic Transmitters**
1	276	22
2	1,032	98
3	792	68
4	2,288	89
5	1,640	134
6	1,624	148

7	3,105	258
8	2,374	194
9	2,385	187
<b>Grand Total</b>	<b>15,516</b>	<b>1198</b>

**Note:** \*4 per 12 months    \*\*1 per 12 months

Continuous Glucose Monitoring is used either with an Insulin pump or used as a stand-alone device (with multiple daily injections) to continuously monitor blood glucose levels in patients with Type 1 Insulin Dependent Diabetes and is a valuable additional tool in helping ensure that in indicated patients the best level of control of their disease is achieved.

I trust that this information is of assistance to you.

Yours sincerely,



**Seán McArt**

General Manager Primary Care  
National Community Operations